Zydus Lifesciences Ltd. has received final nod from the United States Food and Drug Administration to manufacture 60 mg Apalutamide tablets, according to an exchange filing on Tuesday.
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. The tablets will be produced at the company's manufacturing site in Ahmedabad, it said.
Apalutamide tablets had annual sales of nearly $1.1 billion in the US. The group has 420 approvals and so far filed 483 abbreviated new drug applications since the commencement of the filing process in fiscal 2003–04.
Earlier on March 11, the company announced that it would acquire French orthopedics company Amplitude Surgical SA for €300 million or around Rs 2,851 crore. The board approved a put open agreement, share purchase agreement and other agreements to acquire 85.6% stake in Amplitude Surgical for €6.25 per equity share, aggregating to €256.8 million.
Shares of Zydus Lifesciences closed 1.06% higher at Rs 902.15 apiece on the NSE, compared to a 1.45% advance in the benchmark Nifty. The stock has fallen 8.99% in the last 12 months.
Seventeen out of the 33 analysts tracking the company have a 'buy' rating on the stock, 10 recommend 'hold' and six suggest 'sell', according to Bloomberg data. The average of 12-month analyst price targets implies a potential upside of 20.5%.
RECOMMENDED FOR YOU
Indian Tablet PC Market Grows 20% In Q2 FY25; Apple Leads With 30% Share: Cybermedia
Aug 16, 2025
CDSL Arm Gets SEBI's 'No Objection' To Set Up Business Unit In GIFT City
Aug 14, 2025
Oracle Layoffs: Tech Giant Cuts Jobs in Cloud Infrastructure Unit Amid AI Spending
Aug 13, 2025
Government Approves Four Semiconductor Projects Worth Rs 4,600 Crore
Aug 12, 2025
POPULAR